Description

Simple

Clinical

Overview

Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

Pharmacology

Indication

Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.

Pharmacodynamic

Information currently not available.

Mechanism of action

Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with h... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

196 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Matuzumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Matuzumab.
Abituzumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Matuzumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Matuzumab.
Aducanumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Matuzumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Matuzumab.
Alirocumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when Matuzumab is combined with AMG 108.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Matuzumab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Matuzumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Matuzumab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Matuzumab.
Apolizumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Matuzumab is combined with Asfotase alfa.
3 References
  1. 1 . Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K: Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer. 2008 Apr 1;122(7):1530-8.PubMed: 18033688
  2. 2 . Socinski MA: Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4597-601.PubMed: 17671148
  3. 3 . Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F: A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007 Mar;104(3):727-31. Epub 2006 Nov 28.PubMed: 17126894